--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): December 19, 2007
PEDIATRIX MEDICAL GROUP, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Florida 001-12111 65-0271219
------------------------------ ----------------- --------------------
(State or Other (Commission File (IRS Employer
Jurisdiction of Incorporation) Number) Identification No.)
1301 Concord Terrace
Sunrise, Florida 33323
--------------------------------------------------------------------------------
(Address of principal executive office)
Registrant's telephone number, including area code (954) 384-0175
--------------
--------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Item 8.01 Other Events.
On December 19, 2007, Pediatrix Medical Group, Inc. (the "Company") issued a
press release (the "Press Release") announcing that it had signed a definitive
agreement with PerkinElmer, Inc., pursuant to which the Company will sell its
newborn metabolic screening laboratory business in a cash transaction. The
closing of the sale is subject to customary conditions, including the expiration
or termination of the applicable waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976. A copy of the Press Release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
In a separate press release ("Separate Release"), the Company announced that its
Board of Directors authorized an additional share repurchase program, pursuant
to which the Company may purchase up to $100 million of its common stock in open
market purchases based upon price, general economic and market conditions and
trading restrictions. A copy of the Separate Release is attached hereto as
Exhibit 99.2 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1-- Press Release dated December 19, 2007.
99.2-- Press Release dated December 19, 2007.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PEDIATRIX MEDICAL GROUP, INC.
Date: December 19, 2007 By: /s/ Karl B. Wagner
------------------------------
Name: Karl B. Wagner
Title: Chief Financial Officer
--------------------------------------------------------------------------------
EXHIBIT INDEX
Exhibit No. Description
------------ ---------------------------------------------------------------
99.1 Press Release dated December 19, 2007.
99.2 Press Release dated December 19, 2007.